Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats.
The success of targeting systems to alveolar macrophages critically depends on internalization into these cells for pharmacological intervention. Direct respiratory delivery via inhalation of mannose modified liposomal carriers to alveolar macrophages is of great interest. To evaluate the targeting efficiency to alveolar macrophages by intratracheal administration of mannosylated liposomes (Man-liposomes), Man-liposomes with various ratio of mannosylated cholesterol derivatives, cholesten-5-yloxy-N-(4-((1-imino-2-D-thiomannosylethyl)amino)alkyl)formamide (Man-C4-Chol) as mannose receptor ligand were investigated with regard to their in vitro uptake in primary cultured alveolar macrophages and in vivo intratracheal administration in rats. The in vitro uptake of Man-liposomes took place in a concentration-dependent manner. The internalization of Man-liposomes with 7.5% (Man-7.5-liposomes) and 5.0% (Man-5.0-liposomes) Man-C4-Chol was considerably higher than that of Man-liposomes with 2.5% of Man-C4-Chol (Man-2.5-liposomes) and Bare-liposomes and significantly inhibited by an excess of mannan, suggesting mannose receptor-mediated endocytosis. After intratracheal administration of Man-7.5 and Man-5.0-liposomes in rats, a significantly high internalization and selective targeting to alveolar macrophages was observed. The enhanced cellular uptake in alveolar macrophages related to the mannose density of Man-liposomes was also confirmed both in vitro and in vivo confocal microscopy studies. These results demonstrate the efficient targeting to alveolar macrophages by the intratracheally administered Man-liposomes via mannose receptor-mediated endocytosis.
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan.
Wassana
W
Wijagkanalan
Shigeru
S
Kawakami
Mitsuko
M
Takenaga
Rie
R
Igarashi
Fumiyoshi
F
Yamashita
Mitsuru
M
Hashida
D000818:Animals; D002478:Cells, Cultured; D002782:Cholestenes / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D002784:Cholesterol / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D004333:Drug Administration Routes; D016503:Drug Delivery Systems; D004847:Epithelial Cells / Q000378:metabolism; D037181:Lectins, C-Type / Q000378:metabolism; D008081:Liposomes / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D016676:Macrophages, Alveolar / Q000378:metabolism*; D008297:Male; D008351:Mannans / Q000494:pharmacology; D008358:Mannose / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins / Q000378:metabolism; D018613:Microscopy, Confocal; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D011663:Pulmonary Surfactants / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011956:Receptors, Cell Surface / Q000378:metabolism
D002782:Cholestenes; D037181:Lectins, C-Type; D008081:Liposomes; D008351:Mannans; D000090323:Mannose Receptor; D037241:Mannose-Binding Lectins; D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants; D011956:Receptors, Cell Surface; D002784:Cholesterol; C010942:1,2-distearoyllecithin; D008358:Mannose